|
4.12 BIOPSIES LIQUIDES
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
5. TRAITEMENTS
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
|
|
US aims to help more cancer patients try experimental drugs [AP]
|
|
|
|
|
|
Instead of making doctors plead their case first to companies and then to the FDA if the company agrees to provide the drug, the FDA will become the initial step and will assign a staffer to quickly do the paperwork. That way, when a company gets a request, it knows the FDA already considers it appropriate.
|
|
|
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
6.10.1 POLITIQUES (USA)
|
|
|
|
6.12 ETHIQUE
|
|
|
Research integrity is much more than misconduct [Nature]
|
|
|
|
|
|
Research misconduct encompasses fraud, fabrication and plagiarism. It is essential to deal with such dishonesty thoroughly and fairly, but it’s patching up a tear after the damage is done. Research integrity includes such investigations, but it is much more. It is about creating systems that boost the quality, relevance and reliability of all research.
|
|
|
|
|
|
|
6.6 PUBLICATIONS
|
|
|
Plan S Is Still Coming [In The Pipeline]
|
|
|
|
|
|
What’s for sure, I’d think, is that scientific publishing will never again look like it did twenty years ago, or even ten. It’ll come down to the behavior of the next generations of scientists themselves, and their universities, governments, companies, and funding agencies.
|
|
|
|
|
|
|
|
6.7.2 APPLIS
|
|
|
|
6.9 CONTROVERSES
|
|
|